Methotrexate (MTX) remains a cornerstone in the treatment of rheumatoid arthritis, despite the advent of newer biologic therapies, because of its long-term efficacy and safety. However ...

Methotrexate is a cornerstone of therapy ... as has been reported in rheumatoid arthritis. However, preliminary evidence has revealed the association of long-chain MTX polyglutamates 3–5 with ...

A 1-year course of methotrexate may help prevent the development of ACPA-negative RA among patients with clinically suspect arthralgia at high-risk for the disease.

Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...

Predictors of MTX monotherapy treatment success among patients with RA include low disease activity, normal body weight and ESR levels, and fewer tender joints.

Rheumatoid arthritis (RA) is a chronic ... as well as to control inflammation to some degree. Methotrexate (MTX), an older oral DMARD, remains the gold standard of treatment and is included ...

ALLAN GIBOFSKY: In rheumatoid arthritis, a person's immune system ... NEKETIA HENRY: Conventional drugs, such as methotrexate and biologics, are both disease-modifying. However, they are different ...

After they fail methotrexate, it's a TNF inhibitor, almost always Humira. And that's not OK." If there's a shred of hope in this story, it's that a blood test, PrismRA, may herald an era of improved ...

The following is a summary of “High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis,” published in the October 2024 issue ...

The Food and Drug Administration (FDA) has expanded the approval of Jylamvo (methotrexate) to include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL), as part of a ...